Page last updated: 2024-10-27

gabexate and Amyotrophic Lateral Sclerosis

gabexate has been researched along with Amyotrophic Lateral Sclerosis in 1 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Inuzuka, T1
Sato, S1
Baba, H1
Miyatake, T1

Other Studies

1 other study available for gabexate and Amyotrophic Lateral Sclerosis

ArticleYear
Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases.
    Acta neurologica Scandinavica, 1987, Volume: 76, Issue:1

    Topics: Amyotrophic Lateral Sclerosis; Endopeptidases; Esters; Follow-Up Studies; Gabexate; Guanidines; Huma

1987